Clinical Trials Logo

Overall Survival, OS clinical trials

View clinical trials related to Overall Survival, OS.

Filter by:
  • None
  • Page 1

NCT ID: NCT03336554 Recruiting - Clinical trials for Objective Response Rate for Neoadjuvant Chemotherapy, ORR

Epigenetic Biomarker for Osteosarcoma

Start date: September 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down of 5hmC-containing DNA fragments for sequencing. After selectively constructing 5hmC library, highthroughput-sequencing will be performed on an Illumina Nextseq-500 instrument. By ways of Rawdata processing, differential loci between Osteosarcoma group and control group will be detected to indentify specific epigenetic biomarkers of Osteosarcoma.